Nothing Special   »   [go: up one dir, main page]

MX2021010207A - Formulacion farmaceutica de liberacion extendida. - Google Patents

Formulacion farmaceutica de liberacion extendida.

Info

Publication number
MX2021010207A
MX2021010207A MX2021010207A MX2021010207A MX2021010207A MX 2021010207 A MX2021010207 A MX 2021010207A MX 2021010207 A MX2021010207 A MX 2021010207A MX 2021010207 A MX2021010207 A MX 2021010207A MX 2021010207 A MX2021010207 A MX 2021010207A
Authority
MX
Mexico
Prior art keywords
extended release
pharmaceutical formulation
release pharmaceutical
treatment
resistant
Prior art date
Application number
MX2021010207A
Other languages
English (en)
Inventor
Paul William Glue
Natalie June Medlicott
Peter William Surman
Original Assignee
Douglas Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US16/362,848 external-priority patent/US10869838B2/en
Application filed by Douglas Pharmaceuticals Ltd filed Critical Douglas Pharmaceuticals Ltd
Publication of MX2021010207A publication Critical patent/MX2021010207A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La divulgación proporciona una formulación oral de liberación prolongada para el tratamiento de la depresión resistente al tratamiento y la ansiedad resistente al tratamiento.
MX2021010207A 2019-03-25 2020-03-05 Formulacion farmaceutica de liberacion extendida. MX2021010207A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16/362,848 US10869838B2 (en) 2017-10-10 2019-03-25 Extended release pharmaceutical formulation
PCT/IB2020/051909 WO2020194087A2 (en) 2019-03-25 2020-03-05 Extended release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
MX2021010207A true MX2021010207A (es) 2021-09-21

Family

ID=72611620

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021010207A MX2021010207A (es) 2019-03-25 2020-03-05 Formulacion farmaceutica de liberacion extendida.

Country Status (9)

Country Link
EP (1) EP3946296B9 (es)
JP (1) JP7381597B2 (es)
KR (1) KR20220002905A (es)
CN (1) CN113939286A (es)
AU (2) AU2020247549B2 (es)
CA (1) CA3130039A1 (es)
ES (1) ES2982954T3 (es)
MX (1) MX2021010207A (es)
WO (1) WO2020194087A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114288273B (zh) * 2022-02-11 2022-10-18 桂林华信制药有限公司 一种盐酸文拉法辛缓释胶囊及其生产工艺
KR102756768B1 (ko) 2022-08-16 2025-01-21 황성욱 전원 공급 레일 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005005446A1 (de) * 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
RU2493830C2 (ru) * 2008-01-25 2013-09-27 Грюненталь Гмбх Лекарственная форма
EP2393487B1 (en) * 2009-02-06 2016-11-02 Egalet Ltd. Pharmaceutical compositions resistant to abuse
WO2012056246A1 (en) * 2010-10-28 2012-05-03 Shire Llc Combination treatment of major depressive disorder
PH12013501345A1 (en) * 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2996771A4 (en) * 2013-05-13 2016-12-28 Icahn School Med Mount Sinai TREATMENT OF HUMILION AND FEAR STROKES
JP2016531913A (ja) * 2013-08-26 2016-10-13 アモーサ セラピューティックス， インコーポレイテッドＡｍｏｒｓａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 神経抑制性ケタミンの単層による経口投与
PL3215147T3 (pl) * 2014-11-04 2024-06-24 Acadia Pharmaceuticals Inc. Związki norketaminy osłabiającej działanie układu nerwowego i sposoby
US10869838B2 (en) * 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CN111630026A (zh) * 2017-10-10 2020-09-04 道格拉斯制药有限公司 缓释药物制剂和治疗方法

Also Published As

Publication number Publication date
KR20220002905A (ko) 2022-01-07
AU2020247549A1 (en) 2021-09-09
AU2020247549B2 (en) 2024-08-29
EP3946296A4 (en) 2022-12-14
JP2022526233A (ja) 2022-05-24
EP3946296B9 (en) 2024-12-25
CA3130039A1 (en) 2020-10-01
EP3946296A2 (en) 2022-02-09
ES2982954T3 (es) 2024-10-21
WO2020194087A2 (en) 2020-10-01
EP3946296B1 (en) 2024-05-01
ES2982954T9 (en) 2025-03-13
AU2024227388A1 (en) 2024-11-07
WO2020194087A3 (en) 2020-11-26
JP7381597B2 (ja) 2023-11-15
CN113939286A (zh) 2022-01-14

Similar Documents

Publication Publication Date Title
AU2018348359A8 (en) Extended release pharmaceutical formulation and methods of treatment
IL283840A (en) Preparations for administering therapeutic substances and methods for their use and preparation
MX2020006128A (es) Inhibidores de la proteina de activacion de fibroblastos.
MX2020014245A (es) Inhibidores de quinasas dependientes de ciclinas.
GEP20227443B (en) Magl inhibitors
PH12019502646A1 (en) Pyrazole magl inhibitors
MX2017000254A (es) Sistema para la administracion de una composicion de higiene bucal.
MY189820A (en) Oral care compositions and methods of using the compositions
MX2019014042A (es) Inhibidores pirazolicos de magl.
MA40539A (fr) Procédés de formulation de compositions de conjugués anticorps-médicaments
EP3512517B8 (en) Use of pridopidine for the treatment of anxiety and depression
MX2023001963A (es) Composiciones farmaceuticas hipertonicas que contienen un agente quimioprotector antiplatino.
MX2021016050A (es) Formulaciones transdermicas.
CR20210158A (es) Formas de dosificación pediátricas de vitamina d, métodos de elaboración y uso
TWD196337S (zh) 口腔保健器具（一）
ZA201807438B (en) Methods of treating ocular conditions
MX2018000262A (es) Usos terapeuticos de formulaciones de berberina.
MX2021010207A (es) Formulacion farmaceutica de liberacion extendida.
MX2022006312A (es) Inhibidores del receptor de hidrocarburos de arilo (ahr) y usos de los mismos.
MX379440B (es) Moduladores de canales de ca2+ activados de liberación de ca2+ (crac) y usos farmacéuticos de los mismos.
MA40642A (fr) Nouveaux dérivés peptidiques et leurs utilisations
EP3710011C0 (fr) Triterpènes pentacycliques dans le traitement d'une pathologie bucco-dentaire
PH12018502139A1 (en) Phosphaplatin liquid formulations
BR112019023944A2 (pt) combinação farmacêutica para o tratamento de um câncer
EP4537846A3 (en) Anavex2-73 for the treatment of alzheimer s disease